CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Jacob Wackerhausen/iStock via Getty Images CervoMed (NASDAQ:CRVO) has been enrolling for its phase 2b RewinD-LB study, which is using neflamapimod for the treatment of patients with dementia with Lewy bodies [DLB]. The reason to note this biotech is that it had stated that it is on track to complete enrollment of this trial in the 1st half of 2024. Not only that but from there, it is said that it will be able to release results from this phase 2b study in the 2nd half of 2024. This is going to be a major in ...